We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive bladder cancer (NMIBC).
The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication.
The FDA will review this submission under its Real-Time Oncology Review (“RTOR”) program.
The RTOR Program and Its Benefit for J&J
Filings reviewed under the RTOR program enable the agency to start evaluating portions of the application as soon as they are ready, instead of waiting for the entire application to be submitted. This approach has been designed to accelerate the approval process for certain oncology drugs or biologics that aim to address unmet medical needs or provide significant advantages over existing therapies.
TAR-200 is an innovative method developed by J&J for a sustained delivery of chemotherapy drug gemcitabine directly into the bladder. Following a prospective FDA nod, J&J aims to offer a potentially less invasive alternative to the current standard treatment, radical cystectomy (complete bladder removal).
The RTOR program also works alongside the FDA’s other programs to expedite drug development and review. J&J’s TAR-200 has been granted breakthrough therapy designation by the FDA in the given indication.
The FDA filing is supported by data from the phase IIb SunRISe-1 study, which revealed that treatment with J&J’s drug-device combo achieved high effectiveness and durability with an 83.5% complete response (CR) rate without the need for reinduction. Per management, 82% of responders maintained the CR at a median follow-up of nine months.
JNJ Stock Performance
In the past year, J&J’s shares have lost nearly 10% compared with the industry’s 4% decline.
Image Source: Zacks Investment Research
J&J’s Competition in the NMIDC Space
TAR-200 provides a novel treatment approach for an indication with limited therapeutic options, especially for older patients unable or unwilling to undergo radical cystectomy.
If approved, J&J’s TAR-200 will likely hold an edge over ImmunityBio’s (IBRX - Free Report) Anktiva and Merck’s (MRK - Free Report) Keytruda, both of which are approved to treat high-risk NMIBC in patients unresponsive to BCG vaccine. However, the Merck and ImmunityBio drugs utilize a different mechanism of action — IBRX’s Anktiva is an IL-15 antibody drug, approved for intravesical use in combination with the BCG vaccine. MRK’s Keytruda is a blockbuster PD-1 inhibitor approved for use as a single agent. However, it is administered intravenously.
Although primarily used to prevent tuberculosis, the BCG vaccine is also a standard treatment for some forms of bladder cancer.
Image: Bigstock
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
Johnson & Johnson (JNJ - Free Report) has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive bladder cancer (NMIBC).
The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication.
The FDA will review this submission under its Real-Time Oncology Review (“RTOR”) program.
The RTOR Program and Its Benefit for J&J
Filings reviewed under the RTOR program enable the agency to start evaluating portions of the application as soon as they are ready, instead of waiting for the entire application to be submitted. This approach has been designed to accelerate the approval process for certain oncology drugs or biologics that aim to address unmet medical needs or provide significant advantages over existing therapies.
TAR-200 is an innovative method developed by J&J for a sustained delivery of chemotherapy drug gemcitabine directly into the bladder. Following a prospective FDA nod, J&J aims to offer a potentially less invasive alternative to the current standard treatment, radical cystectomy (complete bladder removal).
The RTOR program also works alongside the FDA’s other programs to expedite drug development and review. J&J’s TAR-200 has been granted breakthrough therapy designation by the FDA in the given indication.
The FDA filing is supported by data from the phase IIb SunRISe-1 study, which revealed that treatment with J&J’s drug-device combo achieved high effectiveness and durability with an 83.5% complete response (CR) rate without the need for reinduction. Per management, 82% of responders maintained the CR at a median follow-up of nine months.
JNJ Stock Performance
In the past year, J&J’s shares have lost nearly 10% compared with the industry’s 4% decline.
Image Source: Zacks Investment Research
J&J’s Competition in the NMIDC Space
TAR-200 provides a novel treatment approach for an indication with limited therapeutic options, especially for older patients unable or unwilling to undergo radical cystectomy.
If approved, J&J’s TAR-200 will likely hold an edge over ImmunityBio’s (IBRX - Free Report) Anktiva and Merck’s (MRK - Free Report) Keytruda, both of which are approved to treat high-risk NMIBC in patients unresponsive to BCG vaccine. However, the Merck and ImmunityBio drugs utilize a different mechanism of action — IBRX’s Anktiva is an IL-15 antibody drug, approved for intravesical use in combination with the BCG vaccine. MRK’s Keytruda is a blockbuster PD-1 inhibitor approved for use as a single agent. However, it is administered intravenously.
Although primarily used to prevent tuberculosis, the BCG vaccine is also a standard treatment for some forms of bladder cancer.
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
JNJ’s Zacks Rank
J&J currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.